SinoMab BioScience Ltd (HKSE:03681) Share Price

Company Profile

Business description
SinoMab BioScience Ltd is a biopharmaceutical company. The company is engaged in the research, development, manufacturing, and commercialization of therapeutics for the treatment of immunological diseases, monoclonal antibody (mAb)-based biologics. Its flagship product, SM03 (Suciraslimab), is a potential first-in target mAb for the treatment of rheumatoid arthritis (RA) and potentially for the treatment of other immunological diseases such as systemic lupus erythematosus (SLE), Sjogren’s syndrome (SS) as well as non-Hodgkin’s lymphoma (NHL), and other indications. The group derives revenue from Hong Kong.
Contact
No. 15 Science Park West Avenue
Units 303 and 305 to 307
Hong Kong Science Park, Pak Shek Kok
New Territories
Hong Kong
HKG
T: +852 34269833
https://www.sinomab.com
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2026
Employees
36

Recommended

Shares surged after the announcement of first half fiscal 2026 guidance.

Mark Taylor | 17 April 2026

We maintain our fair value estimate for TSMC stock.

Phelix Lee | 17 April 2026

Trying to make sense of a share caught up in irrational exuberance.

Mark LaMonica, CFA | 17 April 2026

Index	Last price	Change	% Change
All Ordinaries	9,168.70	33.00	0.36%
CAC 40	8,425.13	162.43	1.97%
DAX 40	24,702.24	547.77	2.27%
Dow JONES (US)	49,416.29	837.57	1.72%
FTSE 100	10,667.63	77.64	0.73%
HKSE	26,160.33	233.93	-0.89%
NASDAQ	24,406.66	303.95	1.26%
Nikkei 225	58,475.90	1,042.44	-1.75%
NZX 50 Index	12,905.67	160.39	-1.23%
S&P 500	7,116.06	74.78	1.06%
S&P/ASX 200	8,946.90	36.80	0.41%
SSE Composite Index	4,051.43	4.12	-0.10%